What does Asarfi Hospital do?

Asarfi Hospital Ltd is a micro-cap company in the hospital industry, incorporated in 2005 and converted to a public limited company in 2012. As of March 2025, it reported net sales of 34 Cr and a net profit of 4 Cr, with a market cap of Rs 268 Cr.

Overview: <BR>Asarfi Hospital Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Asarfi Hospital Limited was originally incorporated as a Private Limited Company on October 4, 2005, under the name "Asarfi Hospital Private Limited." The company later converted its status to Public Limited and changed its name to "Asarfi Hospital Limited" on February 08, 2012. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 34 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 268 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.20 <BR>Return on Equity: 15.58% <BR>Price to Book: 3.76 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Has Asarfi Hospital declared dividend?

No Dividend History Available

What is the technical trend for Asarfi Hospital?

As of May 19, 2025, Asarfi Hospital's technical trend is bullish, supported by a positive MACD and moving averages, although the weekly RSI indicates some potential weakness in momentum.

As of 19 May 2025, the technical trend for Asarfi Hospital has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate bullish momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the strength of the current trend. However, the weekly RSI is bearish, suggesting some potential weakness in momentum. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish MACD and moving averages.

Who are the peers of the Asarfi Hospital?

Asarfi Hospital's peers include GPT Healthcare, KMC Speciality, Aashka Hospitals, and others, with varying management risks and growth rates. Asarfi Hospital has a good management risk and a 1-year return of 92.36%, outperforming its peers.

Peers: The peers of Asarfi Hospital are GPT Healthcare, KMC Speciality, Abate As Indust, Aashka Hospitals, Aprameya Enginee, Unihealth Hosp, Chandan Healthca, Nephro Care, KHFM Hospitality, and Maitreya Medica.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare and Chandan Healthca, while Average management risk is found at KMC Speciality and KHFM Hospitality. Good management risk is noted at Asarfi Hospital, Aprameya Enginee, Unihealth Hosp, and Nephro Care, while Below Average management risk is present at Aashka Hospitals. Growth is Excellent at Aprameya Enginee and Nephro Care, Below Average at GPT Healthcare, KMC Speciality, Asarfi Hospital, Aashka Hospitals, and KHFM Hospitality, and does not qualify for Abate As Indust. Capital Structure is Excellent at GPT Healthcare and KMC Speciality, Good at Asarfi Hospital, Nephro Care, and Chandan Healthca, Below Average at Aprameya Enginee, Unihealth Hosp, Aashka Hospitals, and KHFM Hospitality, and does not qualify for Abate As Indust.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Abate As Indust at 46.07%, while the lowest is KMC Speciality at -19.73%. Asarfi Hospital's 1-year return is 92.36%, which is significantly higher than both. Additionally, KMC Speciality, Aashka Hospitals, and KHFM Hospitality have negative six-month returns.

Who are in the management team of Asarfi Hospital?

As of March 2023, the management team of Asarfi Hospital includes Udai Pratap Singh (Managing Director), Madhuri Singh (Executive Director), Sukanti Kumar Das (Director), Amit Kumar Barnwal (Independent Director), Rajkumari Sharma (Independent Director), and Seepika Gupta (Company Secretary & Compliance Officer). Each member contributes to the hospital's governance and operations.

As of March 2023, the management team of Asarfi Hospital includes the following individuals:<BR><BR>1. Udai Pratap Singh - Managing Director<BR>2. Madhuri Singh - Executive Director<BR>3. Sukanti Kumar Das - Director<BR>4. Amit Kumar Barnwal - Independent Director<BR>5. Rajkumari Sharma - Independent Director<BR>6. Seepika Gupta - Company Secretary & Compliance Officer<BR><BR>Each member plays a crucial role in the governance and operational oversight of the hospital.

Who are the top shareholders of the Asarfi Hospital?

The top shareholders of Asarfi Hospital include Harendra Singh with 18.78%, followed by public shareholder Gopal Singh at 2.4%. Individual investors collectively own 30.86% of the shares, with no pledged promoter holdings or involvement from mutual funds or foreign institutional investors.

The top shareholders of Asarfi Hospital primarily consist of the promoters, with Harendra Singh holding the largest stake at 18.78%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors involved. The highest public shareholder is Gopal Singh, who holds 2.4%. Additionally, individual investors collectively own 30.86% of the shares.

How big is Asarfi Hospital?

As of 24th July, Asarfi Hospital Ltd has a market capitalization of 261.00 Cr, with net sales of 110.87 Cr and a net profit of 6.01 Cr over the last four quarters. Shareholder's funds are 70.41 Cr, and total assets amount to 154.09 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Asarfi Hospital Ltd has a market capitalization of 261.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 110.87 Cr, while the sum of Net Profit for the same period is 6.01 Cr.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2024. Shareholder's Funds stand at 70.41 Cr, and Total Assets amount to 154.09 Cr.

When is the next results date for Asarfi Hospital?

Asarfi Hospital will declare its results on 07 August 2025.

Asarfi Hospital will declare its results on 07 August 2025.

Are Asarfi Hospital latest results good or bad?

Asarfi Hospital's Q2 FY26 results are strong, with a net profit of ₹4.20 crores, a 47.37% year-on-year increase, and revenue growth of 45.46% to ₹44.89 crores, marking the highest quarterly revenue in its history. The operating margin is 19.76%, indicating solid profitability and effective capital management.

Asarfi Hospital's latest results for Q2 FY26 are quite strong, indicating a positive performance. The company reported a net profit of ₹4.20 crores, which reflects a significant increase of 47.37% year-on-year and a 34.62% sequential growth from the previous quarter. Additionally, revenue grew by 45.46% year-on-year, reaching ₹44.89 crores, marking the highest quarterly revenue in the company's history.<BR><BR>The operating margin stands at a healthy 19.76%, showcasing the company's ability to maintain profitability while scaling operations. Furthermore, the return on equity is a commendable 15.99%, indicating effective capital management.<BR><BR>Overall, the results highlight Asarfi Hospital's robust growth trajectory and operational efficiency, positioning it well within the healthcare sector.

How has been the historical performance of Asarfi Hospital?

Asarfi Hospital experienced significant growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 120.57 Cr and profit after tax increasing to 10.58 Cr. However, cash flow from operating activities turned negative, indicating challenges in cash management despite strong revenue performance.

Answer:<BR>The historical performance of Asarfi Hospital shows significant growth from the previous year, with net sales increasing from 84.40 Cr in Mar'24 to 120.57 Cr in Mar'25. Total operating income mirrored this growth, rising to 120.57 Cr from 84.40 Cr. The total expenditure also increased, from 68.35 Cr to 97.01 Cr, primarily driven by higher raw material costs and other expenses. Operating profit (PBDIT) rose to 31.08 Cr from 17.72 Cr, while profit before tax improved from 6.24 Cr to 14.31 Cr. Consequently, profit after tax saw a substantial increase from 4.16 Cr to 10.58 Cr, resulting in an earnings per share (EPS) growth from 2.11 to 5.38. <BR><BR>In terms of balance sheet performance, shareholder's funds increased to 80.98 Cr from 70.41 Cr, and total liabilities rose to 163.89 Cr from 154.09 Cr. Long-term borrowings also increased significantly from 17.45 Cr to 33.83 Cr. Current assets improved to 58.48 Cr from 45.60 Cr, with notable increases in sundry debtors and inventories. However, cash flow from operating activities turned negative, dropping from 26.00 Cr to -4.00 Cr, while cash flow from financing activities decreased from 36.00 Cr to 12.00 Cr. Overall, Asarfi Hospital demonstrated strong revenue and profit growth, despite challenges in cash flow management.

Should I buy, sell or hold Asarfi Hospital?

Is Asarfi Hospital overvalued or undervalued?

As of November 14, 2025, Asarfi Hospital is considered overvalued with a PE ratio of 31.38 and an EV to EBITDA of 16.34, despite strong stock performance, indicating it may not be an attractive investment compared to peers like Apollo Hospitals and Max Healthcare.

As of 14 November 2025, Asarfi Hospital's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.38, an EV to EBITDA of 16.34, and a PEG ratio of 0.20, which suggests growth potential relative to its valuation. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE ratio of 63.77 and an EV to EBITDA of 33.53, while Max Healthcare is marked as very expensive with a PE of 89.07. Despite the recent strong stock performance, with a year-to-date return of 75.1% compared to the Sensex's 8.22%, the elevated valuation metrics indicate that Asarfi Hospital may not present an attractive investment opportunity at current levels.

Which are the latest news on Asarfi Hospital?

Why is Asarfi Hospital falling/rising?

As of 03-Dec, Asarfi Hospital Ltd's stock price is at 200.95, down 0.75 (-0.37%). Despite this minor decline, the stock has shown strong overall performance with significant gains year-to-date and over the past year, although reduced trading volume and institutional interest may be affecting investor confidence.

As of 03-Dec, Asarfi Hospital Ltd's stock price is currently at 200.95, reflecting a decrease of 0.75 (-0.37%). Despite this slight decline, the stock has shown strong performance over various periods, including a 1-week increase of 0.80% and a remarkable 32.68% rise over the past month. Year-to-date, the stock has surged by 100.95%, and over the last year, it has generated a return of 130.98%, significantly outperforming the market benchmark, which has only returned 5.27% in the same timeframe.<BR><BR>The company's financial health appears robust, with a low Debt to EBITDA ratio of 1.44 times, indicating a strong ability to service its debt. Additionally, the company reported a net profit growth of 34.38% and has declared positive results for the last two consecutive quarters. The highest net sales recorded at Rs 44.89 crore and a substantial growth in profit before tax further underscore its strong operational performance.<BR><BR>However, the stock is experiencing a slight decline today, which may be attributed to falling investor participation, as evidenced by a 2.44% decrease in delivery volume compared to the 5-day average. Furthermore, there is a noted decrease in institutional investor stakes, which may contribute to a perception of reduced confidence in the stock's future performance.<BR><BR>In summary, while Asarfi Hospital Ltd has demonstrated impressive growth and market-beating returns, the current minor decline in its stock price can be linked to reduced trading volume and institutional interest, despite its strong fundamentals and positive financial results.